孟鲁司特合博利康尼防治儿童咳嗽变异性哮喘_医学论文.docVIP

孟鲁司特合博利康尼防治儿童咳嗽变异性哮喘_医学论文 孟鲁司特合博利康尼防治儿童咳嗽变异性哮喘_医学论文 【摘要】 目的： 观察孟鲁司特联合博利康尼治疗儿童咳嗽变异性哮喘的临床疗效。方法：对照组40例给予博利康尼片口服，治疗组40例口服博利康尼片加用孟鲁司特钠咀嚼片。两组咳嗽症状消失后均停用博利康尼片，治疗组继续服用孟鲁司特钠咀嚼片，总疗程8周。停药后随访9个月，观察咳嗽复发、哮喘转化及不良反应情况。结果：治疗组疗效明显优于对照组，差异有显著性意义(0.05)在咳嗽症状复发数、典型哮喘转化率和不良反应方面，治疗组均比对照组明显降低(0.05)。结论：孟鲁司特联合博利康尼治疗儿童咳嗽变异性哮喘临床疗效好，副作用少。 【关键词】 儿 童 咳嗽变异性哮喘 孟鲁司特 博利康尼 Montelukast Combined with Turbutaline to Treat Cough Variant Asthma in Children YANG Fang,et al.The Third Hospital Affiliated to Wenzhou Medical College,Wenzhou(325200),China 　　Abstract Objective:To study the efficacy of montelukast combined with turbutaline on the prevention of cough variant asthma in children.Methods:Forty patients were treated with turbutaline and montelukast sodium chewable tablets.Another 40 patients who were taken turbutaline orally served as control.After symptoms disappearing,turbutaline treatment was ceased in both groups and montelukast administration continued till the eighth week.Recurrence of cough,asthma conversion and adverse events had been followed up for 9 months.Results:The therapeutic efficacy in the treatment group was significantly higher than that in the control group(0.05).The recurrent rate of cough,asthma conversion and adverse events were less in the treatment group than those in the control group (0.05).Conclusion:Montelukast combined with turbutaline has effect on cough variant asthma with little side effect in children. 　　Key words children cough variant asthma montelukast turbutaline 　　咳嗽变异性哮喘(cough variant asthma，CVA)过去称过敏性咳嗽，是一种以咳嗽为主而无喘息症状和特征的特殊类型哮喘，其实质是慢性气道炎症[1]，是小儿慢性咳嗽的常见病因之一，临床以顽固性咳嗽、反复发作为特征。吸入糖皮质激素(吸入激素)是治疗所有类型哮喘的首选药物。白三烯修饰剂可用于治疗运动性哮喘及阿司匹林哮喘，单用吸入激素治疗症状控制不理想的哮喘患者，加用白三烯受体拮抗剂(孟鲁司特)治疗，可使症状得到显著改善[2]。国外已有小样本研究显示孟鲁司特治疗CVA疗效较好[3,4]。笔者采用前瞻性研究方法，观察孟鲁司特联合博利康尼治疗CVA的疗效，并以单纯博利康尼治疗为对照，现报道如下。 　　1 临床资料 　　2005年4月～2007年5月我院儿科门诊或住院咳嗽变异性哮喘患儿80例，均符合2005年咳嗽的诊断与治疗指南(草案)[1]。其中男49例，女31例，男女之比为1.81∶1，年龄1～14岁，平均5.6±3.0岁，病程1～24个月，平均5.2±2.3个月。80例随机分成治疗组与对照组，各40例。治疗组男23例，女17例，平均年龄5.5±2.6岁。对照组男26例，女14例，平均年龄5.7±3.